Reviva Pharmaceuticals Holdings, Inc. Gain (Loss) on Derivative Instruments, Net, Pretax
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Gain (Loss) on Derivative Instruments, Net, Pretax of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-12-31 was $44.51K.
- Reviva Pharmaceuticals Holdings, Inc. gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-09-30 was -$27.82K, a 138.46% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2025 was $89.01K, a 87.60% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2024 was $717.64K.
- Reviva Pharmaceuticals Holdings, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2023 was -$239.22K.
- Reviva Pharmaceuticals Holdings, Inc. gain (loss) on derivative instruments, net, pretax for fiscal 2022 was -$194.71K, a 112.24% decline from fiscal 2021.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month | Gain (Loss) on Derivative Instruments, Net, Pretax 11 month | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $44.51K derived: sum of 3 quarters · filed 2026-08-12 | $16.69K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $44.51K derived: sum of 2 quarters · filed 2026-05-13 | $16.69K derived: sum of 3 quarters · filed 2026-05-13 | $27.82K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $44.51K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $16.69K derived: sum of 2 quarters · filed 2026-03-30 | $27.82K derived: sum of 3 quarters · filed 2026-08-12 | $89.01K 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$27.82K 10-Q · filed 2025-11-13 | -$16.69K derived: sum of 2 quarters · filed 2026-08-12 | $44.50K 10-Q · filed 2025-11-13 | $33.38K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $11.13K 10-Q · filed 2026-08-12 | $72.32K 10-Q · filed 2026-08-12 | $61.19K derived: sum of 3 quarters · filed 2026-08-12 | $133.51K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $61.19K 10-Q · filed 2026-05-13 | $50.07K derived: sum of 2 quarters · filed 2026-05-13 | $122.39K derived: sum of 3 quarters · filed 2026-05-13 | $322.66K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$11.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $61.20K derived: sum of 2 quarters · filed 2026-03-30 | $261.47K derived: sum of 3 quarters · filed 2026-03-30 | $717.64K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $72.32K 10-Q · filed 2025-11-13 | $272.59K derived: sum of 2 quarters · filed 2025-11-13 | $728.77K 10-Q · filed 2025-11-13 | $795.53K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $200.27K 10-Q · filed 2025-08-14 | $656.45K 10-Q · filed 2025-08-14 | $723.21K derived: sum of 3 quarters · filed 2025-08-14 | $862.28K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $456.18K 10-Q · filed 2025-05-15 | $522.93K derived: sum of 2 quarters · filed 2025-05-15 | $662.01K derived: sum of 3 quarters · filed 2025-05-15 | $205.84K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $66.76K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $205.84K derived: sum of 2 quarters · filed 2025-04-03 | -$250.34K derived: sum of 3 quarters · filed 2025-04-03 | -$239.22K 10-K · filed 2025-04-03 | |
| 2023-09-30 | $139.08K 10-Q · filed 2024-11-14 | -$317.10K derived: sum of 2 quarters · filed 2024-11-14 | -$305.97K 10-Q · filed 2024-11-14 | -$767.71K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$456.18K 10-Q · filed 2024-08-14 | -$445.05K 10-Q · filed 2024-08-14 | -$906.79K derived: sum of 3 quarters · filed 2024-08-14 | -$906.79K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $11.13K 10-Q · filed 2024-05-14 | -$450.61K derived: sum of 2 quarters · filed 2024-05-14 | -$450.61K derived: sum of 3 quarters · filed 2024-05-14 | -$272.59K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$461.74K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | -$461.74K derived: sum of 2 quarters · filed 2024-04-15 | -$283.72K derived: sum of 3 quarters · filed 2024-04-15 | -$194.71K 10-K · filed 2024-04-15 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | $178.02K derived: sum of 2 quarters · filed 2023-11-14 | $267.03K 10-Q · filed 2023-11-14 | $545.19K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $178.02K 10-Q · filed 2023-08-14 | $267.03K 10-Q · filed 2023-08-14 | $545.19K derived: sum of 3 quarters · filed 2023-08-14 | $745.46K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $89.01K 10-Q · filed 2023-05-15 | $367.17K derived: sum of 2 quarters · filed 2023-05-15 | $567.44K derived: sum of 3 quarters · filed 2023-05-15 | $756.59K derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $278.16K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $478.43K derived: sum of 2 quarters · filed 2023-03-30 | $667.58K derived: sum of 3 quarters · filed 2023-03-30 | $1.59M 10-K · filed 2023-03-30 | |
| 2021-12-13 | $1.59M 10-K · filed 2022-03-15 | ||||
| 2021-09-30 | $200.27K 10-Q · filed 2022-11-14 | $389.42K derived: sum of 2 quarters · filed 2022-11-14 | $1.31M 10-Q · filed 2022-11-14 | $1.31M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $189.15K 10-Q · filed 2022-08-15 | $1.11M 10-Q · filed 2022-08-15 | $1.11M derived: sum of 3 quarters · filed 2022-08-15 | $1.11M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $923.48K 10-Q · filed 2022-05-16 | $923.48K derived: sum of 2 quarters · filed 2022-05-16 | $923.48K derived: sum of 3 quarters · filed 2022-05-16 | $923.48K derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |